{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:01:16Z","timestamp":1781640076639,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018558","name":"Shanghai Shuguang Program","doi-asserted-by":"publisher","award":["22SG36"],"award-info":[{"award-number":["22SG36"]}],"id":[{"id":"10.13039\/501100018558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902733"],"award-info":[{"award-number":["81902733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018625","name":"Science and Technology Innovation Plan Of Shanghai Science and Technology Commission","doi-asserted-by":"publisher","award":["23Y11903600"],"award-info":[{"award-number":["23Y11903600"]}],"id":[{"id":"10.13039\/501100018625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>Retrospective cohort study<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare systemic therapy outcomes between separation surgery and maximal feasible resection for patients with spinal metastases from non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of background data<\/jats:title>\n                    <jats:p>The presence of bone metastases has been associated with diminished response of primary tumors to systemic therapy, especially immunotherapy. However, in patients with spinal metastases, the impact of varying degrees of bone metastatic burden reduction on the efficacy of subsequent systemic therapy remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Adult patients (\u226518 years) with spinal metastases from NSCLC who underwent surgical intervention at our institution between between January 2019 and June 2024 were retrospectively identified. Patients were categorized into two groups based on surgical strategy: separation surgery (SS) or maximal feasible resection (MFR). Systemic therapy response (objective response rate, disease control rate and best overall response) was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Surgical outcomes included blood loss, operating time, intraoperative blood transfusion, and complications. Overall survival (OS) was analyzed using the Kaplan\u2013Meier method, and differences between groups were compared using the log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 36 patients with spinal metastases from NSCLC were included. Patients in the MFR group exhibited a significantly higher disease control rate compared to those in the SS group (71.4% vs. 27.3%, P = 0.024). However, MFR was associated with increased surgical morbidity, including greater intraoperative blood loss [median 800 mL (IQR: 650\u20131425) vs. 500 mL (IQR: 100\u20131000), P = 0.041], a higher rate of intraoperative blood transfusion (71.4% vs. 31.8%, P = 0.048), and more intraoperative complications (28.6% vs. 0%, P = 0.017). There was no statistically significant difference in overall survival between the two surgical strategies [median 23.7 months (95% CI: 18.8\u201329.4) vs. 20.6 months (95% CI: 17.5\u201322.5); HR = 0.42 (95% CI: 0.16\u20131.08); P = 0.065]. However, Exploratory subgroup analyses indicated that MFR combined with denosumab was associated with a significantly lower hazard of death compared with SS plus bisphosphonates (HR = 0.14, 95% CI: 0.03\u20130.61, P = 0.009) and MFR plus bisphosphonates (HR = 0.15, 95% CI: 0.02\u20130.95, P = 0.044). A non-significant trend was also observed versus SS combined with denosumab (HR = 0.34, 95% CI: 0.10\u20131.18, P = 0.088).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared to SS, MFR was associated with improved outcomes of subsequent systemic therapy in patients with spinal metastases from NSCLC, albeit at the cost of increased surgical trauma and a higher risk of intraoperative complications. In addition, MFR was associated primarily with disease stabilization rather than objective tumor regression. Notably, the combination of MFR with denosumab was associated with longer overall survival. These findings support the consideration of MFR in carefully selected patients, particularly when optimizing the response to systemic therapy is a key clinical objective. Importantly, given the small sample size, the observed differences in disease control rate and subgroup survival should be interpreted as hypothesis-generating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence<\/jats:title>\n                    <jats:p>Level IV<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-026-04300-y","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T02:15:03Z","timestamp":1773195303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapy outcomes following separation surgery versus maximal feasible resection for spinal metastases from non-small cell lung cancer: a real-world retrospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhilong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"1","key":"4300_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4300_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47\u201353.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"4300_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1748-717X-8-200","volume":"8","author":"H Rief","year":"2013","unstructured":"Rief H, et al. The stability of osseous metastases of the spine in lung cancer\u2013a retrospective analysis of 338 cases. Radiat Oncol. 2013;8(1):200.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4300_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s00586-022-07444-z","volume":"32","author":"J Zheng","year":"2023","unstructured":"Zheng J, et al. Prognostic factors and outcomes of surgical intervention for patients with spinal metastases secondary to lung cancer: an update systematic review and meta analysis. Eur Spine J. 2023;32(1):228\u201343.","journal-title":"Eur Spine J"},{"issue":"23","key":"4300_CR5","first-page":"2438","volume":"323","author":"RG Chiu","year":"2020","unstructured":"Chiu RG, Mehta AI. Spinal Metastases Jama. 2020;323(23):2438.","journal-title":"Spinal Metastases Jama"},{"issue":"4","key":"4300_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, et al. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(4):249\u201374.","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"4300_CR7","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"4300_CR8","doi-asserted-by":"crossref","unstructured":"Cheng JN et al. Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts. Cancer Cell. 2025;43(6):1093\u20131107.e9.","DOI":"10.1016\/j.ccell.2025.03.036"},{"key":"4300_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","volume":"166","author":"YJ Zhu","year":"2022","unstructured":"Zhu YJ, et al. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays cold immune characteristics in Non-small cell lung cancer. Lung Cancer. 2022;166:189\u201396.","journal-title":"Lung Cancer"},{"issue":"1","key":"4300_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.21037\/tlcr-21-1033","volume":"11","author":"H Qiang","year":"2022","unstructured":"Qiang H, et al. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study. Transl Lung Cancer Res. 2022;11(1):87\u201399.","journal-title":"Transl Lung Cancer Res"},{"issue":"7624","key":"4300_CR11","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"21","key":"4300_CR12","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1200\/JCO.2017.72.7362","volume":"35","author":"O Barzilai","year":"2017","unstructured":"Barzilai O, et al. Integrating Evidence-Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease. J Clin Oncol. 2017;35(21):2419\u201327.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4300_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12957-025-04009-4","volume":"23","author":"ZZ Shen","year":"2025","unstructured":"Shen ZZ, et al. Maximal feasible resection versus hybrid therapy in spinal metastases: an updated narrative review. World J Surg Oncol. 2025;23(1):357.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"4300_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"4300_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0031-1296049","volume":"1","author":"JJ van Middendorp","year":"2011","unstructured":"van Middendorp JJ, et al. Diagnosis and prognosis of traumatic spinal cord injury. Global Spine J. 2011;1(1):1\u20138.","journal-title":"Global Spine J"},{"issue":"3","key":"4300_CR16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3171\/2010.3.SPINE09459","volume":"13","author":"MH Bilsky","year":"2010","unstructured":"Bilsky MH, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324\u20138.","journal-title":"J Neurosurg Spine"},{"issue":"19","key":"4300_CR17","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1097\/01.brs.0000180401.06919.a5","volume":"30","author":"Y Tokuhashi","year":"2005","unstructured":"Tokuhashi Y, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005;30(19):2186\u201391.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"22","key":"4300_CR18","doi-asserted-by":"publisher","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","volume":"35","author":"CG Fisher","year":"2010","unstructured":"Fisher CG, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35(22):E1221\u20139.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"4300_CR19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00586-021-07032-7","volume":"31","author":"S Cao","year":"2022","unstructured":"Cao S, et al. A comparison of two different surgical procedures in the treatment of isolated spinal metastasis patients with metastatic spinal cord compression: a case-control study. Eur Spine J. 2022;31(6):1583\u20139.","journal-title":"Eur Spine J"},{"issue":"9","key":"4300_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/BRS.0000000000005207","volume":"50","author":"J Amelink","year":"2025","unstructured":"Amelink J, et al. Comparative Analysis of Surgical Outcomes in Separation Surgery Versus Anterior Reconstruction for Metastatic Epidural Spinal Cord Compression. Spine (Phila Pa 1976). 2025;50(9):612\u20139.","journal-title":"Spine (Phila Pa 1976)"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04300-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:47:21Z","timestamp":1781639241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4300"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04300-y","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of Shanghai Changzheng Hospital, and the requirement for informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent for publication of the data was waived by the Medical Ethics Committee of Shanghai Changzheng Hospital, given the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}